Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Daily News

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

Yael L. Maxwell

August 14, 2025

News Daily News

TEER May Surpass Medical Therapy in High-risk Atrial FMR Patients

Caitlin E. Cox

August 13, 2025

$Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis$

News Daily News

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

Todd Neale

August 13, 2025

News Conference News NY Valves 2025

No Benefit of Sentinel Device During TAVI: Updated Meta-analysis

Todd Neale

July 04, 2025

News Conference News NY Valves 2025

MitraClip Safe and Effective in Non-COAPT-Like Patients: EXPANDed

Yael L. Maxwell

July 03, 2025

News Daily News

Trade-offs With Invasive Strategy in Older Patients With ACS: Meta-analysis

Michael O'Riordan

July 03, 2025

News Daily News

‘Sobering’ Adverse Event Rate With Evoque Seen in Real-world Use

Yael L. Maxwell

June 18, 2025

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

L.A. McKeown

May 30, 2025

News Daily News EuroPCR 2025

Underexpanded Acurate neo2 Valves Tied to Worse Outcomes: ACURATE IDE

Michael O'Riordan

May 28, 2025

News Conference News EuroPCR 2025

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

Michael O'Riordan

May 23, 2025

News Conference News EuroPCR 2025

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

Yael L. Maxwell

May 23, 2025

News Conference News EuroPCR 2025

Higher Mortality With TAVI Over Surgery in Bicuspid Aortic Stenosis

Michael O'Riordan

May 22, 2025

News Conference News EuroPCR 2025

Meta-analysis Quashes Hopes for Routine Embolic Protection in TAVI

Michael O'Riordan

May 21, 2025

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

News Conference News ACC 2025

EARLY TAVR: Delaying Valve Replacement Increases Risk of Poor Outcomes

L.A. McKeown

April 07, 2025

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

L.A. McKeown

March 30, 2025

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

L.A. McKeown

March 10, 2025

Advertisement

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

TEER May Surpass Medical Therapy in High-risk Atrial FMR Patients

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

No Benefit of Sentinel Device During TAVI: Updated Meta-analysis

MitraClip Safe and Effective in Non-COAPT-Like Patients: EXPANDed

Trade-offs With Invasive Strategy in Older Patients With ACS: Meta-analysis

‘Sobering’ Adverse Event Rate With Evoque Seen in Real-world Use

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

Underexpanded Acurate neo2 Valves Tied to Worse Outcomes: ACURATE IDE

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

Higher Mortality With TAVI Over Surgery in Bicuspid Aortic Stenosis

Meta-analysis Quashes Hopes for Routine Embolic Protection in TAVI

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

EARLY TAVR: Delaying Valve Replacement Increases Risk of Poor Outcomes

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content